Panacea Index Logo

Command Palette

Search for a command to run...

Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials.

American journal of Alzheimer's disease and other dementias
August 1, 2015
Jing Xu et al. (7 authors)
Journal ArticleMeta-AnalysisResearch Support, Non-U.S. Gov'tReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the effectiveness of melatonin therapy for improving sleep disturbances and cognitive function in patients with dementia.

Results Summary

Melatonin therapy prolonged total sleep time by 24.36 minutes and marginally improved sleep efficacy, particularly with interventions lasting more than 4 weeks, but did not significantly impact cognitive function. No severe adverse events were reported.

Population

Patients with dementia experiencing sleep disturbances.

Effective Dosage

Not specified

Duration

More than 4 weeks for stronger effects

Interactions

None mentioned

Extracted Claims (4)
InterventionDirectionEndpointPopulationDosageImpactClaim #
melatonin therapy
increase
total sleep time (TST)
patients with dementia
24.36 minutes
prolonged
#1
melatonin therapy
increase
sleep efficacy (SE)
patients with dementia
-
marginally improved
#2
melatonin therapy
no change
cognitive function
patients with dementia
-
did not change significantly
#3
melatonin therapy
no change
severe adverse events
patients with dementia
-
no report of
#4
Abstract

The current review aims to examine melatonin therapy for both sleep disturbances and cognitive function in dementia. We searched all randomized controlled trials published in Medline, Embase, the Cochrane Library, China National Knowledge Infrastructure, the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register, and Clinical Trials.gov. The grading of recommendations assessment, development and evaluation framework was used to assess the quality of evidence. Seven studies were included (n = 520). Treated participants showed prolonged total sleep time (TST) by 24.36 minutes (P = .02). Sleep efficacy (SE) was marginally improved (P = .07). This effect was stronger under a longer intervention period lasting more than 4 weeks (P = .02). Conversely, cognitive function did not change significantly. Additionally, there was no report of severe adverse events. Given the current studies, we conclude that melatonin therapy may be effective in improving SE and prolonging TST in patients with dementia; however, there is no evidence that this improvement impacts cognitive function.

Medical Subject Headings (MeSH)
Alzheimer DiseaseCentral Nervous System DepressantsCognitionCognition DisordersDementiaDementia, VascularHumansMelatoninRandomized Controlled Trials as TopicSleep Wake Disorders
Study Links
Quality Scores
Safety90
Efficacy70/10
Quality85/10
Citation Metrics
Total Citations77
Citations/Year7.7
Relative Citation Ratio3.30
NIH Percentile86.9%
Research Impact Scores
APT Score0.95
Weight Score1.99
Normalized Score0.81
Related Supplements